Most recently, Kathleen Metters was the senior vice president in charge of worldwide basic research at Merck -- a 20 year veteran there, reports Ed Sliverman, on this.
In addition, the local Ann Arbor online paper covered the Merck/Metters/Lycera connection quite well -- do go read it all -- but here's an interesting bit:
. . . .Lycera hired Kathleen Metters, former senior vice president and head of worldwide basic research for global pharmaceutical company Merck, as its new CEO. The appointment comes seven months after Lycera struck a research and licensing deal with Merck that could be worth more than $300 million. . . .
The hiring also comes after Lycera signed a deal to lease 14,134 square feet of offices and lab space at an ex-Pfizer building now owned by the University of Michigan.
Lycera is developing therapies to treat various autoimmune diseases, including rheumatoid arthritis, psoriasis and multiple sclerosis. . . .
We'll keep an eye on this company, and Ms. Metters, for the readership.
No comments:
Post a Comment